Evaluation of the attitude of patients suffering from psychiatric disease and staff personal in psychiatric hospitals regarding clinical studies underlying the German Drug law.
- Conditions
- F20F32F33F25SchizophreniaDepressive episodeSchizoaffective disordersRecurrent depressive disorder
- Registration Number
- DRKS00009619
- Lead Sponsor
- VR-Klinik Köln
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
Patientgroup 1:
actually treatment in hospital
age 18-65 years
diagnosis (ICD10): F32 and F33
Patientgroup 2:
actually treatment in hospital
age 18-65 years
diagnosis (ICD10): F20 and F25
medical staff group 1:
physicians in psychiatric hospital
medical staff group 2:
nurses in psychaitric hospital
Exclusion Criteria
enforced stay in hospital
limited contractual capability
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The staff personal groups physicians and nurses are asked to fullfill one-time-only the questionaire.<br><br>Primary endpoint:<br>Group comparison of the sum score in the questionaire Attitude of sphysicians and careers to clinical studies underlying the GML.
- Secondary Outcome Measures
Name Time Method Both patientgroups are asked to fullfill one-time-only the questionaires Attitude of patients suffering from psychiatric diseases to clinical studies underlying the GML and the DAI-10, German version.<br><br>Hypothesis 2:<br>Groupcomparison of patientgroup 1 and patientgroup 2. Sumscore of the questionaire Attitude of patients suffering from psychiatric diseases to clinical studies underlying the GML. <br><br><br>Hypothesis 3:<br>Evaluation of the sumscore of the questionaire Attitude of patients suffering from psychiatric diseases to clinical studies underlying the GML and sumscore of the questionaire DAI-10, German version.<br>- Correlation of both sumscores in patientgroup 1.<br>- Correlation of both sumscores in patientgroup 2.